Navegando por Palavras-chave "misoprostol"
Agora exibindo 1 - 5 de 5
Resultados por página
Opções de Ordenação
- ItemAcesso aberto (Open Access)Can the Induction of Labor with Misoprostol Increase Maternal Blood Loss?(Federacao Brasileira Soc Ginecologia & Obstetricia-Febrasgo, 2017) Praciano Souza, Paulo Cesar; Azevedo Damasceno, Karla Santana; Araujo Junior, Edward [UNIFESP]; Alencar Junior, Carlos Augusto; de Lucena Feitosa, Francisco EdsonPurpose To evaluate blood loss during misoprostol-induced vaginal births and during cesarean sections after attempted misoprostol induction. Methods We conducted a prospective observational study in 101 pregnant women indicated for labor induction
- ItemSomente MetadadadosInduction of Labor using Misoprostol in a Tertiary Hospital in the Southeast of Brazil(Federacao Brasileira Soc Ginecologia & Obstetricia-Febrasgo, 2017) Godoy Silva, Tacito Augusto; Borges Junior, Luciano Eliziario; Tahan, Luisa Almeida; Arantes Costa, Taynna Ferreira; Magalhaes, Fernanda Oliveira; Peixoto, Alberto Borges; Martins, Wellington de Paula; Araujo Junior, Edward [UNIFESP]Purpose To assess cases of labor induction with vaginal 25-mu g tablets of misoprostol and maternal outcomes in a tertiary hospital in southeastern Brazil. Methods This was a retrospective cohort study of 412 pregnant women with indication for labor induction. Labor induction was performed with vaginal 25-mu g tablets ofmisoprostol in pregnant women with Bishop scores < 6. Stepwise regression analysis was used to identify the factors present at the beginning of induction that could be used as predictors of successful labor induction. Results A total of 69% of the pregnant women who underwent labor induction progressed to vaginal delivery, and 31% of the women progressed to cesarean section. One or two misoprostol tablets were used in 244 patients (59.2%). Of the 412 patients, 197 (47.8%) required oxytocin later on in the labor process, after induction with misoprostol. The stepwise regression analysis showed that only Bishop scores of 4 and 5 and previous vaginal delivery were independent factors with statistical significance in the prediction of successful vaginal labor induction (beta = 0.23, p < 0.001, for a Bishop score of 4 and 5, and beta = 0.22, p < 0.001, for previous vaginal delivery). Conclusion Higher Bishop scores and previous vaginal delivery were the best predictors of successful labor induction with vaginal 25-mu g tablets of misoprostol.
- ItemSomente MetadadadosMobius sequence in children exposed in utero to misoprostol: Neuropathological study of three cases(Wiley-Blackwell, 2003-12-01) Marques-Dias, M. J.; Gonzalez, C. H.; Rosemberg, S.; Universidade de São Paulo (USP); Universidade Federal de São Paulo (UNIFESP)BACKGROUND: Misoprostol exposure in the first trimester of pregnancy has been related to congenital malformations, particularly the Mobius sequence and terminal transverse limb defects. CASES: Neuropathological findings of three patients with Mobius sequence related to misoprostol are reported. No previous pathological studies have shown these abnormalities to be associated with misoprostol exposure in utero. the brain stem was cut serially, from the rostral mesencephalum to,the caudal aspect of the medulla, and all fragments were stained with hematoxylin-eosin and cresyl violet. Old ischemic-anoxic foci of gliosis, with necrosis and calcification, dorsally situated, were present from the pons to the medulla, involving some cranial nerve nuclei (especially the IV, VII and XII) that were partially or completely depopulated of neural cells. CONCLUSIONS: the findings suggest a circulatory mechanism to the Mobius sequence, with vascular disruption involving the territory of the subdavian artery, occurring in a critical period of embryonic life between six to eight weeks postconception. These cases add further evidence of the role of misoprostol as a teratogen. (C) 2003 Wiley-Liss, Inc.
- ItemAcesso aberto (Open Access)Möbius Syndrome: Misoprostol Use and Speech and Language Characteristics(Fundação Otorrinolaringologia, 2014-09-01) Guedes, Zelita Caldeira Ferreira; Universidade Federal de São Paulo (UNIFESP)Introduction Möbius syndrome (MS; VI and VII palsy) is a rare disease that in Brazil has a great frequency because of the use of misoprostol during pregnancy. Objective Verify if the speech and language performance of children with MS whose mothers reported use of misoprostol (Cytotec, Pfizer, Connecticut, USA) are different from the performance of children of mothers who did not report use. Methods The stomatognathic system beyond receptive and expressive language and speech was evaluated in children with MS, and their mothers were questioned whether they used misoprostol during the pregnancy. Results During the interview, 61.11% of mothers reported that they took misoprostol during the pregnancy. Most of the subjects (83.3%) whose mothers took misoprostol presented bilateral palsy beyond bad mobility of the tongue (90.9%) and speech disorders (63.6%). Conclusion The number of mothers who took misoprostol without knowing the risk for MS was great. The lack of facial expressions and speech disorders were common characteristics of the individuals with MS, whether the mothers took misoprostol during the pregnancy or not.
- ItemSomente MetadadadosPregnancy outcome after exposure to misoprostol in Brazil: A prospective, controlled study(Elsevier B.V., 1999-03-01) Schuler, L.; Pastuszak, A.; Sanseverino, MTV; Orioli, I. M.; Brunoni, D.; Ashton-Prolla, P.; Costa, F. S. da; Giugliani, R.; Couto, A. M.; Brandao, S. B.; Koren, G.; Hosp Sick Children; Univ Fed Rio Grande Sul; Clin Hosp; Universidade Federal do Rio de Janeiro (UFRJ); Universidade Federal de São Paulo (UNIFESP); Univ TorontoBackground: Misoprostol, a synthetic prostaglandin E1 analog is labeled for the treatment of gastric and duodenal ulcers, in Brazil, where abortion is not a legal procedure, there is a widespread popular misuse of this drug in abortion attempts. This misuse and the fact that, in many cases the desired pregnancy termination does not occur, raise concerns about fetal safety. Case reports of congenital anomalies after maternal use of misoprostol have been published. the objective of this work was to compare pregnancy outcome following misoprostol exposure with a matched control group, This is the first prospective controlled study on fetal safety after misoprostol use. Methods: A prospective, observational cohort study with 86 exposed and 86 pair-matched, non-exposed controls. Results: There was no significant difference in the rates of major or minor birth between exposed compared to non-exposed infants (2/67 vs 2/81, major defects; 7/67 vs. 3/81, minor anomalies) There were significantly more miscarriages in the exposed group (17.1% vs, 5.8%; relative risk, 2.97; 95% confidence interval, 1.12 to 7.88), There was no statistical difference in gestational age at delivery, birth weight, sex ratio, rate of prematurity, low birth weight, or rates of cesarean section between groups. Conclusions: Our study, despite its limited statistical power, does not suggest a potent teratogenic action of misoprostol exposure during pregnancy. (C) 1999 Elsevier Science Inc.